Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781572 | 0.85 | MCL1 (0.41) | PRMT1FGFR1BCL2MDM2MCL1 | |
| SCHEMBL19781260 | 0.84 | PRMT1 (0.39) | PRMT1FGFR1NPC1BCL2MDM2 | |
| SCHEMBL22032809 | 0.81 | NPBWR1 (0.40) | PRMT1FGFR1NPC1BCL2MDM2 | |
| SCHEMBL22032799 | 0.81 | PRMT1 (0.39) | PRMT1FGFR1NPC1BCL2MDM2 | |
| SCHEMBL21436073 | 0.81 | CYP2A6 (0.34) | PRMT1BTK | |
| SCHEMBL22071831 | 0.80 | BCL2 (0.44) | FGFR1RAB9ABCL2MDM2MCL1 | |
| SCHEMBL22032810 | 0.80 | KMT2A (0.37) | PRMT1FGFR1BCL2MDM2MCL1 | |
| SCHEMBL28678500 | 0.77 | HDAC3 (0.42) | NPC1RAB9AKMT2ANPSR1MAPK6 | |
| SCHEMBL21449912 | 0.76 | MDM2 (0.42) | BCL2MDM2MCL1KMT2A | |
| SCHEMBL22071834 | 0.76 | PTGES (0.44) | PRMT1BCL2MDM2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | PRMT1 2276/4885FGFR1 3952/4885NPC1 162/4885 |
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | HAVCR2, ZC3HAV1, CD4 | PRMT1 3569/4885FGFR1 4440/4885NPC1 52/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | PRMT1 2223/4885FGFR1 3928/4885NPC1 182/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | PRMT1 2223/4885FGFR1 3928/4885NPC1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.